

## WEST Search History

[Hide Items](#)[Restore](#)[Clear](#)[Cancel](#)

DATE: Tuesday, October 18, 2005

Hide?	Set Name	Query	Hit Count
		<i>DB=USPT; PLUR=NO; OP=OR</i>	
<input type="checkbox"/>	L4	L3 and display and variegat\$\$\$\$	28
<input type="checkbox"/>	L3	librar\$\$\$\$ same cdr	404
<input type="checkbox"/>	L2	variegated same cdr	4
<input type="checkbox"/>	L1	6906176.pn.	1

END OF SEARCH HISTORY

(FILE 'HOME' ENTERED AT 13:39:05 ON 18 OCT 2005)

FILE 'REGISTRY' ENTERED AT 13:39:23 ON 18 OCT 2005

L1 1042 S RASQ.V...LA/SQSP  
L2 1623 S I..SGG.T.YADSVKG/SQSP  
L3 0 S L2&L1/SQSFP  
L4 3 S L2 AND L1

FILE 'CAPLUS' ENTERED AT 13:41:52 ON 18 OCT 2005

L5 2 S L4 AND LIBRAR?  
L6 3 S L4

FILE 'REGISTRY' ENTERED AT 13:44:27 ON 18 OCT 2005

L7 464 S AYAMA/SQSP  
L8 0 S L7 AND L1  
L9 0 S L7 AND L2  
L10 1665 S AASSAA/SQSP  
L11 0 S L10 AND L7  
L12 0 S QQYAAAPAT/SQSP  
L13 0 S TGTSSDVGTYDYVS/SQSP

FILE 'CAPLUS, MEDLINE, SCISEARCH, BIOSIS' ENTERED AT 13:50:07 ON 18 OCT 2005

L14 0 S VARIEGATED LIBRAR?  
L15 1 S VARIEGATED AND CDR AND LIBRAR?  
E LADNER ROBERT CHARLES/AU  
L16 122 S E1-E3  
L17 0 S L15 AND L16  
L18 1 S L16 AND CDR AND LIBRAR?  
L19 1 S L16 AND VECTOR# AND VARIEGATE?

L15 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1995:892928 CAPLUS  
 DN 123:308167  
 ED Entered STN: 03 Nov 1995  
 TI Process for generating antibodies specific for immunorecessive epitopes by generation of display **library** of variable regions from immunotolerance-derived antibodies  
 IN Barsomian, Gary; Copeland, Diane P.; Hillhouse, Dana; Johnson, Tracy  
 PA Genzyme Corp., USA  
 SO PCT Int. Appl., 109 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM C07K016-00  
 ICS C12N015-13  
 CC 3-1 (Biochemical Genetics)  
 Section cross-reference(s): 15

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9515982	A2	19950615	WO 1994-US14106	19941208
	WO 9515982	A3	19951228		
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2175482	AA	19950615	CA 1994-2175482	19941208
	AU 9514321	A1	19950627	AU 1995-14321	19941208
	AU 696293	B2	19980903		
	EP 733070	A1	19960925	EP 1995-905871	19941208
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 09506262	T2	19970624	JP 1994-516337	19941208
PRAI	US 1993-164022	A	19931208		
	US 1994-350400	A	19941206		
	US 1994-164022	A	19941206		
	WO 1994-US14106	W	19941208		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9515982	ICM	C07K016-00
	ICS	C12N015-13
WO 9515982	ECLA	C07K016/00; C12N015/62

AB The present invention relates to a method for generating an antibody which is specific for an immunorecessive epitope, and nucleic acid encoding the antibody. The subject method generally comprises the steps of generating a **variegated display library** of antibody variable regions, and selecting from the **library** those antibody variable regions which have a desired binding specificity for the immunorecessive epitope. The antibody variable regions used to generate the display **library** are cloned from an immunotolerance-derived antibody repertoire. Thus, a specific antibody to an immunorecessive epitope (such as metastatic tumor cell or fetal nucleated red blood cell markers or tumor suppressor protein p53 mutants) can be generated by affinity purification of an antibody phage **library** derived from an immunotolerance-derived antibody repertoire. Using the described technique, fetal blood cell-specific Fab' fragments with  $K_a$  of  $6-8 + 10^{10} \text{ M}^{-1}$  were prepared. These antibodies were  $\geq 40$ -fold more specific than prior art antibodies produced by hybridoma or immunotolerance techniques. Addnl., the antibody display phages were enriched 5000- to  $3.6 + 10^6$ -fold in a single round of selection by panning on live cells.

ST antibody immunorecessive epitope specific phage display; immunotolerance technique immunorecessive epitope specific antibody

IT Erythrocyte  
 (antigenic marker for fetal; process for generating antibodies specific for immunorecessive epitopes by generation of display **library** of variable regions from immunotolerance-derived antibodies)

IT Nerve  
 (antigenic marker for precursor pf; process for generating antibodies

2003  
01/19/03

specific for immunorecessive epitopes by generation of display **library** of variable regions from immunotolerance-derived antibodies)

IT Hematopoietic precursor cell  
Neoplasm  
(antigenic marker for; process for generating antibodies specific for immunorecessive epitopes by generation of display **library** of variable regions from immunotolerance-derived antibodies)

IT Antigens  
RL: MSC (Miscellaneous)  
(immunorecessive epitope-containing; process for generating antibodies specific for immunorecessive epitopes by generation of display **library** of variable regions from immunotolerance-derived antibodies)

IT Escherichia coli  
Virus, bacterial  
(process for generating antibodies specific for immunorecessive epitopes by generation of display **library** of variable regions from immunotolerance-derived antibodies)

IT Antibodies  
RL: BPN (Biosynthetic preparation); BIOL (Biological study); PREP (Preparation)  
(process for generating antibodies specific for immunorecessive epitopes by generation of display **library** of variable regions from immunotolerance-derived antibodies)

IT Lipoproteins  
RL: ANT (Analyte); ANST (Analytical study)  
(apo-, E4, process for generating antibodies specific for immunorecessive epitopes by generation of display **library** of variable regions from immunotolerance-derived antibodies)

IT Intestine, neoplasm  
(colon, antigenic marker for; process for generating antibodies specific for immunorecessive epitopes by generation of display **library** of variable regions from immunotolerance-derived antibodies)

IT Embryo  
(fetus, antigenic marker for cells of; process for generating antibodies specific for immunorecessive epitopes by generation of display **library** of variable regions from immunotolerance-derived antibodies)

IT G proteins (guanine nucleotide-binding proteins)  
RL: ANT (Analyte); ANST (Analytical study)  
(gene c-ras, variants; process for generating antibodies specific for immunorecessive epitopes by generation of display **library** of variable regions from immunotolerance-derived antibodies)

IT Neoplasm  
(metastatic, antigenic marker for; process for generating antibodies specific for immunorecessive epitopes by generation of display **library** of variable regions from immunotolerance-derived antibodies)

IT Cell  
(stem, antigenic marker for; process for generating antibodies specific for immunorecessive epitopes by generation of display **library** of variable regions from immunotolerance-derived antibodies)

IT Phosphoproteins  
RL: ANT (Analyte); ANST (Analytical study)  
(tumor suppressor, p53, variants; process for generating antibodies specific for immunorecessive epitopes by generation of display **library** of variable regions from immunotolerance-derived antibodies)

IT 169182-78-9 169182-79-0 169182-80-3 169182-81-4 169182-82-5  
169182-83-6  
RL: PRP (Properties)  
(CDR-containing region of anti-onco/fetal antigen antibody; process for generating antibodies specific for immunorecessive epitopes by generation of display **library** of variable regions from immunotolerance-derived antibodies)

IT 169800-18-4 169800-19-5 169800-20-8 169800-21-9 169800-22-0

169800-24-2 169800-26-4 169800-28-6 169800-30-0 169800-32-2  
169800-34-4

RL: PRP (Properties)

(amino acid sequence; process for generating antibodies specific for immunorecessive epitopes by generation of display **library** of variable regions from immunotolerance-derived antibodies)

IT 169681-92-9 169681-93-0 169681-94-1 169681-95-2 169681-96-3  
169681-97-4 169681-98-5 169681-99-6

RL: PRP (Properties)

(heavy chain CDR3 of anti-onco/fetal antigen antibody; process for generating antibodies specific for immunorecessive epitopes by generation of display **library** of variable regions from immunotolerance-derived antibodies)

IT 169682-00-2 169682-01-3 169682-02-4 169682-03-5 169682-04-6  
169682-05-7 169682-06-8 169682-07-9 169682-08-0 169682-09-1  
169682-10-4

RL: PRP (Properties)

(light chain CDR3 of anti-onco/fetal antigen antibody; process for generating antibodies specific for immunorecessive epitopes by generation of display **library** of variable regions from immunotolerance-derived antibodies)

IT 169800-23-1 169800-25-3 169800-27-5 169800-29-7 169800-31-1  
169800-33-3

RL: PRP (Properties)

(nucleotide sequence; process for generating antibodies specific for immunorecessive epitopes by generation of display **library** of variable regions from immunotolerance-derived antibodies)